We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 18 AUGUST 2015
Generic Competitor's Regulatory Issues Prompt Stay Of Lialda® Patent Litigation
Haug Partners
As set forth in the decision, Mylan's failure to respond to a deficiency letter received from FDA in May 2014 "raise[d] serious questions in the Court's mind as to the viability of Mylan's ANDA product as currently formulated."
United StatesIntellectual Property









